SM
ALXN

Sabby Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Sabby Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-27,856
Closed -$3.88M – 354
2016
Q1 		$3.88M Buy
27,856
+25,900
+1,324% +$3.8M 0.19% 55
2015
Q4 		$373K Sell
1,956
-47,441
-96% -$8.29M 0.02% 254
2015
Q3 		$7.72M Buy
49,397
+33,502
+211% +$6.11M 0.32% 51
2015
Q2 		$2.87M Buy
+15,895
New +$2.74M 0.1% 133

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Sabby Management's ALXN Position: Q2 2016 in Review

Sabby Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2016, closing a stake of 27,856 shares — an estimated $3.88M sold.

Sabby Management first reported a position in ALXN in Q2 2015 and held it in 4 quarters. The position peaked at $7.72M in Q3 2015. 533 funds tracked by Wall St. Rank hold ALXN as of Q2 2016.

  • Sabby Management reported no remaining Alexion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Sabby Management sold 27,856 Alexion Pharmaceuticals shares in Q2 2016, an estimated $3.88M.
  • Sabby Management first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 4 quarters.
  • Sabby Management's Alexion Pharmaceuticals position peaked at $7.72M in Q3 2015.
  • 533 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2016.

Based on Sabby Management's 13F filing for Q2 2016, filed 15 Aug 2016.